David Gentien

发表

MB-77MOLECULAR SUBGROUPING OF MEDULLOBLASTOMA WITH NANOSTRING TECHNOLOGY: A FEASIBILITY STUDY FOR ROUTINE REAL-TIME PROCEDURES.

Olivier Delattre, Franck Bourdeaut, Julien Masliah-Planchon, 2016 .

Transcriptome Analysis of Wnt3a-Treated Triple-Negative Breast Cancer Cells

Guillem Rigaill, David Gentien, Thierry Dubois, 2015, PloS one.

Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER).

Thomas Bachelot, Florence Dalenc, Thomas Filleron, 2014, The Lancet. Oncology.

Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay

Philippe Ruminy, David Gentien, Randy D Gascoyne, 2017, Haematologica.

Molecular profiling of patient-derived breast cancer xenografts

Anne Vincent-Salomon, Olivier Delattre, David Gentien, 2012, Breast Cancer Research.

SF3B1 mutations are associated with alternative splicing in uveal melanoma.

David Gentien, Samra Turajlic, Laurence Desjardins, 2013, Cancer discovery.

TTK/hMPS1 Is an Attractive Therapeutic Target for Triple-Negative Breast Cancer

Emmanuel Barillot, Anne Vincent-Salomon, Guillem Rigaill, 2013, PloS one.

Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer.

Emmanuel Barillot, Anne Vincent-Salomon, Guillem Rigaill, 2013, Cancer research.

articleA genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer

Jérôme Couturier, Jean-Philippe Meyniel, David Gentien, 2015 .

Genomic Instability: A Stronger Prognostic Marker Than Proliferation for Early Stage Luminal Breast Carcinomas

Roman Rouzier, Anne Vincent-Salomon, Guillem Rigaill, 2013, PloS one.

Standardized Whole-Blood Transcriptional Profiling Enables the Deconvolution of Complex Induced Immune Responses.

Vincent Rouilly, Lluis Quintana-Murci, David Gentien, 2016, Cell reports.

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.

Nicolas Servant, Anne Vincent-Salomon, Xavier Paoletti, 2015, The Lancet. Oncology.

Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patients

Jean-Marc Guinebretière, Nicolas Servant, Bernard Asselain, 2011, BMC Cancer.

Genomic Copy Number Profiling Using Circulating Free Tumor DNA Highlights Heterogeneity in Neuroblastoma

Gudrun Schleiermacher, Olivier Delattre, David Gentien, 2016, Clinical Cancer Research.